0.7301
price down icon1.07%   -0.0079
 
loading
Scynexis Inc stock is traded at $0.7301, with a volume of 59,679. It is down -1.07% in the last 24 hours and down -2.52% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.738
Open:
$0.73
24h Volume:
59,679
Relative Volume:
0.39
Market Cap:
$28.49M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
0.5142
EPS:
1.42
Net Cash Flow:
$45.09M
1W Performance:
+0.70%
1M Performance:
-2.52%
6M Performance:
-31.77%
1Y Performance:
-64.98%
1-Day Range:
Value
$0.73
$0.7439
1-Week Range:
Value
$0.701
$0.7439
52-Week Range:
Value
$0.66
$2.21

Scynexis Inc Stock (SCYX) Company Profile

Name
Name
Scynexis Inc
Name
Phone
201-884-5485
Name
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Name
Employee
29
Name
Twitter
@scynexis
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
SCYX's Discussions on Twitter

Compare SCYX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
SCYX
Scynexis Inc
0.7301 28.80M 135.87M 72.20M 45.09M 1.42
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.12 68.04B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.48 46.30B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.88 44.25B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.54 18.73B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
304.50 13.82B 2.99B 1.21B 1.13B 25.06

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-22-21 Initiated Guggenheim Buy
Jan-06-21 Initiated Cantor Fitzgerald Overweight
Jul-11-18 Upgrade Needham Hold → Buy
Jun-27-18 Initiated Maxim Group Buy
Oct-24-17 Initiated Guggenheim Buy
Jul-10-17 Initiated ROTH Capital Buy
May-09-17 Downgrade Needham Buy → Hold
Mar-03-17 Reiterated RBC Capital Mkts Outperform
Oct-20-16 Initiated H.C. Wainwright Buy
Oct-07-16 Upgrade WBB Securities Buy → Strong Buy
Oct-03-16 Resumed Brean Capital Buy
Aug-17-16 Initiated Guggenheim Buy
Aug-09-16 Reiterated Needham Buy
Aug-09-16 Upgrade WBB Securities Speculative Buy → Buy
Mar-28-16 Initiated Brean Capital Buy
Dec-29-15 Initiated WBB Securities Speculative Buy
Nov-16-15 Reiterated RBC Capital Mkts Outperform
Jun-10-15 Initiated Needham Buy
May-29-14 Initiated Canaccord Genuity Buy
May-29-14 Initiated RBC Capital Mkts Outperform
View All

Scynexis Inc Stock (SCYX) Latest News

pulisher
Jul 24, 2025

Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about SCYNEXIS Inc. stockUnstoppable profit momentum - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 19, 2025

Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News

Jul 19, 2025
pulisher
Jul 16, 2025

What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jul 15, 2025
pulisher
Jul 02, 2025

SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail

Jul 02, 2025
pulisher
Jun 26, 2025

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks

Jun 26, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 15, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Biosergen taps antifungal expert as board member - Biostock

Jun 05, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 03, 2025
pulisher
May 29, 2025

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

May 29, 2025
pulisher
May 29, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey

May 29, 2025
pulisher
May 28, 2025

Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks

May 28, 2025
pulisher
May 28, 2025

SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus

May 28, 2025
pulisher
May 28, 2025

GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times

May 28, 2025

Scynexis Inc Stock (SCYX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.93
price up icon 2.82%
$14.92
price up icon 1.57%
$9.41
price up icon 0.64%
drug_manufacturers_specialty_generic RDY
$14.67
price down icon 0.27%
$132.14
price up icon 0.38%
$304.50
price down icon 0.62%
Cap:     |  Volume (24h):